Moors & Cabot Inc. Purchases Shares of 5,200 Vera Therapeutics, Inc. (NASDAQ:VERA)

Moors & Cabot Inc. purchased a new stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 5,200 shares of the company’s stock, valued at approximately $220,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. AlphaQuest LLC bought a new position in shares of Vera Therapeutics in the 4th quarter worth approximately $34,000. KBC Group NV raised its position in shares of Vera Therapeutics by 127.2% in the 4th quarter. KBC Group NV now owns 2,477 shares of the company’s stock worth $105,000 after acquiring an additional 1,387 shares in the last quarter. E Fund Management Co. Ltd. raised its position in shares of Vera Therapeutics by 22.3% in the 4th quarter. E Fund Management Co. Ltd. now owns 6,203 shares of the company’s stock worth $262,000 after acquiring an additional 1,130 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. raised its position in shares of Vera Therapeutics by 109.4% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 9,407 shares of the company’s stock worth $416,000 after acquiring an additional 4,914 shares in the last quarter. Finally, Intech Investment Management LLC bought a new position in shares of Vera Therapeutics in the 3rd quarter worth approximately $475,000. Institutional investors own 99.21% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on VERA. Wells Fargo & Company began coverage on Vera Therapeutics in a research report on Thursday, November 21st. They issued an “overweight” rating and a $70.00 target price for the company. The Goldman Sachs Group started coverage on Vera Therapeutics in a research report on Tuesday, January 28th. They issued a “buy” rating and a $58.00 target price for the company. Guggenheim upped their price target on Vera Therapeutics from $59.00 to $61.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. JPMorgan Chase & Co. cut their price target on Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 4th. Finally, Wolfe Research started coverage on Vera Therapeutics in a research note on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Vera Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $64.67.

Vera Therapeutics Stock Performance

Shares of VERA opened at $27.99 on Monday. The business’s fifty day simple moving average is $33.01 and its two-hundred day simple moving average is $39.64. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. Vera Therapeutics, Inc. has a 12 month low of $25.99 and a 12 month high of $51.61. The company has a market cap of $1.78 billion, a price-to-earnings ratio of -10.72 and a beta of 1.17.

Vera Therapeutics (NASDAQ:VERA) last issued its earnings results on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.11. Research analysts anticipate that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Insider Buying and Selling at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 17,500 shares of the stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $43.07, for a total transaction of $753,725.00. Following the sale, the chief executive officer now directly owns 85,942 shares in the company, valued at approximately $3,701,521.94. This trade represents a 16.92 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 21.70% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.